Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.64 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.64 |
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.43 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL7836361 | 1.00 | TSHR (0.64) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL4348837 | 1.00 | TSHR (0.64) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL30425683 | 1.00 | TSHR (0.64) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL27732723 | 0.97 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL28692589 | 0.97 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL8172317 | 0.97 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL8071716 | 0.97 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL27732721 | 0.97 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL4237193 | 0.89 | TSHR (0.69) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL4240001 | 0.89 | TSHR (0.69) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110963983-A | Preparation method of cinepazide maleate | 康普药业股份有限公司 | 2020-04-07 | — | — | CN | claimed |
| CN-106432077-A | Preparation method of pixantrone dimaleate | 海正辉瑞制药有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-119661556-A | Pharmaceutically acceptable salts of condensed ring compounds, crystalline forms and uses thereof | 苏州盛迪亚生物医药有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119661555-A | Pharmaceutically acceptable salts of condensed ring compounds, crystalline forms and uses thereof | 苏州盛迪亚生物医药有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2024109871-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, CRYSTAL FORM THEREOF, AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2024-05-30 | — | — | WO | disclosed |
| CN-117567466-B | Preparation method of quinazoline derivative | 成都金瑞基业生物科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117567466-A | Preparation method of quinazoline derivative | 成都金瑞基业生物科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117355524-A | Pharmaceutically acceptable salt of pyrazoloheteroaryl derivative and crystal form thereof | 江苏恒瑞医药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023236485-A1 | ARTEMISININ DERIVATIVES, PREPARATION METHOD THEREFOR, AND USES THEREOF | 上海英诺富成生物科技有限公司 | 2023-12-14 | — | — | WO | disclosed |
| CN-116514832-A | Crystal form of oxazabicyclo derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022242753-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF PYRAZOLOHETEROARYL DERIVATIVE AND CRYSTAL FORM THEREOF | 江苏恒瑞医药股份有限公司 | 2022-11-24 | — | — | WO | disclosed |
| US-5473066-A | Cyclization, acetylation, hydrolysis, stereoselectivity | SHIONOGI & CO., LTD. (JP) | 1995-12-05 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
| EP-0609031-A1 | Process for preparing benzothiazepine derivatives | SHIONOGI & CO., LTD. (JP) | 1994-08-03 | — | — | EP | disclosed |
| US-4826847-A | CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-05-02 | — | — | US | disclosed |
| CN-86105229-A | To eyes beta blocker selectively | — | 1987-04-22 | — | — | CN | disclosed |
| US-4603134-A | ANTIHISTAMINES | FERRER INTERNATIONAL, S.A. (ES) | 1986-07-29 | — | — | US | disclosed |
| US-4522824-A | ADRENERGIC BLOCKING AGENTS | SANOFI (FR) | 1985-06-11 | — | — | US | disclosed |
| US-4281010-A | FOR INCREASING BLOOD CIRCULATION | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-07-28 | — | — | US | disclosed |
| US-4254269-A | PRECURSERS FOR CARDIOVASCULAR DRUGS | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-03-03 | — | — | US | disclosed |